Prostate Cancer
First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients.
January 24, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
January 24, 2024
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
January 24, 2024
Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer.
January 24, 2024
Primary Care Physician and Urologist Perspectives on Optimizing Active Surveillance for Low-Risk Prostate Cancer.
January 24, 2024
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.
January 24, 2024
Functional Outcomes After Localized Prostate Cancer Treatment
January 23, 2024
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET.
January 23, 2024
Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review.
January 23, 2024
Oncologic Outcome of the Extent of Pelvic Lymph Node Dissection During Radical Prostatectomy: A Systematic Review, Meta-analysis, and Network Analysis.
January 23, 2024
Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
January 22, 2024